(SeaPRwire) – SHANGHAI, March 19, 2026 — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a prominent provider of AI-powered digital healthcare services, has announced its 2025 financial results, highlighting robust revenue expansion and a return to full-year profitability as its AI-integrated chronic disease management platform continues to grow. Total revenue climbed 30.2% year-on-year to RMB 3.53 billion in 2025, fueled by consistent growth in consumer-facing segments, such as comprehensive medical services and online pharmacy retail, which saw a combined increase of approximately 30%. The Company reported a net profit of RMB 12 million, surpassing market forecasts and reversing the net loss recorded in 2024. Adjusted net profit rose by 19% to reach RMB 20.4 million. These results underscore the sustained momentum of Fangzhou’s primary business lines and confirm the success of its doctor-patient relationship model, which serves as the foundation for its chronic care services.
Operational performance saw marked improvements, with the registered user base exceeding 56.4 million and average monthly active users rising 35% to 13.7 million. Strong customer loyalty, reflected in a repeat purchase rate of over 85%, continues to bolster recurring revenue. Furthermore, Fangzhou expanded its healthcare ecosystem, with the number of physicians on the platform reaching 251,000 and its pharmaceutical supply chain offering 217,000 SKUs, of which roughly 62% are prescription medications.
The Company also forged strategic alliances with major pharmaceutical firms, including Novo Nordisk, Otsuka, and Innovent Biologics, to enhance its integrated service offerings.
Throughout 2025, Fangzhou accelerated its AI integration, utilizing its ‘XingShi’ Large Language Model (XS LLM) as the core of its “AI + Chronic Disease Management” ecosystem, incorporating AI into consultations, medication management, and follow-up care. Consumer-facing tools, such as AI health managers and medication assistants, provided 24/7 support, improving patient adherence and the overall user experience. For medical professionals, AI assistants helped alleviate administrative burdens, allowing for a greater focus on clinical duties. Additionally, Fangzhou began testing AI-Avatar Doctors, which allow physicians to scale their online consultations through virtual support.
Beyond clinical use, Fangzhou utilized AI to streamline internal operations—including procurement, supply chain management, and content creation—thereby boosting efficiency and profit margins. The Company also advanced its ecosystem strategy through partnerships, such as a deeper collaboration with Tencent Health to deploy AI-driven chronic care solutions.
Fangzhou remains committed to long-term growth through technological innovation and user-centric services. With the expansion of China’s chronic disease population and increased policy support for AI-enabled healthcare, the Company intends to further integrate AI across its ecosystem, broaden its partnerships, and deepen cooperation with the government’s social healthcare insurance system. Fangzhou will continue to invest in digital innovation to enhance healthcare accessibility and efficiency, supporting the broader goals of China’s “Healthy China 2030” initiative.
About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is a leading Chinese online platform for chronic disease management, supporting 56.4 million registered users and 251,000 physicians as of December 31, 2025. The Company specializes in providing personalized medical care and AI-driven precision medicine. For more details, visit https://investors.jianke.com.
Media Contact
For inquiries or interview requests, please contact:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ significantly from those projected due to various risks and uncertainties. Readers are advised not to place undue reliance on these statements.
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.